Ardelyx, Inc. (FRA:41X)
Germany · Delayed Price · Currency is EUR 4.959
-0.139 (-2.73%)
Last updated: Dec 1, 2025, 8:19 AM CET
Ardelyx Company Description
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis.
The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Ardelyx, Inc.
| Country | United States |
| Founded | 2007 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 395 |
| CEO | Michael Raab |
Contact Details
Address: 400 Fifth Avenue Waltham, Delaware 02451 United States | |
| Phone | 510 745 1700 |
| Website | ardelyx.com |
Stock Details
| Ticker Symbol | 41X |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Michael Raab | Chief Executive Officer |
| Sue Hohenleitner | Chief Financial Officer |
| Caitlin Lowie | Head of Investor Relations |